JPH05500973A - 化学的組成物 - Google Patents
化学的組成物Info
- Publication number
- JPH05500973A JPH05500973A JP3511358A JP51135891A JPH05500973A JP H05500973 A JPH05500973 A JP H05500973A JP 3511358 A JP3511358 A JP 3511358A JP 51135891 A JP51135891 A JP 51135891A JP H05500973 A JPH05500973 A JP H05500973A
- Authority
- JP
- Japan
- Prior art keywords
- taurolidine
- taurultam
- administered
- treatment
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1)腫瘍生長の進行または危険にさらされている哺乳動物患者にタウロリジンお よび/またはタウルルタムの有効用量を投与することからなる、該患者の腫瘍の 治療または予防の方法。 2)タウロリジンおよび/またはタウルルタムを注射もしくは注入により投与す るか、または外部腫瘍に対する直接適用により投与する請求項1記載の方法。 3)タウロリジンおよび/またはタウルルタムを1日当たり150〜450mg /kgの用量で投与する請求項1または2記載の方法。 4)タウロリジンおよび/またはタウルルタムを1日当たり300〜450mg /kgの用量で投与する請求項3記載の方法。 5)リンパ腫、肉腫、メラノーマおよびガン腫の治療または予防のための請求項 1〜4のいずれか1項に記載の方法。 6)さらに該哺乳動物患者に細胞傷害剤または腫瘍代謝に包含されることの知ら れている剤を別々にまたは同時に投与する請求項1〜5のいずれか1項に記載の 方法。 7)さらにγ−インターフェロン、インターロイキン−1、インターロイキン− 2、アドリアマイシンまたはアクチノマイシンDを投与する請求項6記載の方法 。 8)哺乳動物患者の腫瘍の治療または予防におけるタウロリジンおよび/または タウルルタムの使用。 9)哺乳動物患者の腫瘍の治療または予防用医薬組成物の調製におけるタウロリ ジンおよび/またはタウルルタムの使用。 10)腫瘍生長の進行または危険にさらされている哺乳動物患者に対する個別ま たは同時投与用の、タウロリジンおよび/またはタウルルタム、並びに細胞傷害 剤または腫瘍代謝に包含される剤から選択される少なくとも1種の剤を含有する 医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9015108.5 | 1990-07-09 | ||
GB909015108A GB9015108D0 (en) | 1990-07-09 | 1990-07-09 | Chemical compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05500973A true JPH05500973A (ja) | 1993-02-25 |
JP3465824B2 JP3465824B2 (ja) | 2003-11-10 |
Family
ID=10678847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51135891A Expired - Lifetime JP3465824B2 (ja) | 1990-07-09 | 1991-07-08 | 腫瘍治療用医薬組成物 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0491018A1 (ja) |
JP (1) | JP3465824B2 (ja) |
GB (1) | GB9015108D0 (ja) |
WO (1) | WO1992000743A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002363102A (ja) * | 2001-04-03 | 2002-12-18 | Ed Geistlich Soehne Ag Fuer Chemische Industrie | 新形成細胞の細胞消滅死を誘導する方法 |
JP2010043115A (ja) * | 2000-11-28 | 2010-02-25 | Ed Geistlich Soehne Ag Fuer Chemische Industrie | 腫瘍転移および癌の治療における5−フルオロウラシルの有効性の増強 |
JP2010043114A (ja) * | 2000-10-27 | 2010-02-25 | Ed Geistlich Soehne Ag Fuer Chemische Industrie | 腫瘍転移および癌の治療 |
US7892530B2 (en) | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
US7910580B2 (en) | 1999-06-04 | 2011-03-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-Fluorouracil in treatment of tumor metastases and cancer |
US8030301B2 (en) | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
JP2012136540A (ja) * | 1999-12-06 | 2012-07-19 | Geistlich Pharma Ag | 腫瘍を治療する方法 |
US8304390B2 (en) | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19606897C2 (de) * | 1996-02-13 | 2002-08-29 | Geistlich Soehne Ag | Mittel zur Verhinderung der Tumorzellverschleppung und der Entstehung von Trokarmetastasen in der offenen und laparoskopischen Chirurgie maligner Tumoren |
GB9716219D0 (en) * | 1997-07-31 | 1997-10-08 | Geistlich Soehne Ag | Prevention of metastases |
US6479481B1 (en) | 1999-06-04 | 2002-11-12 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
US7151099B2 (en) | 1998-07-31 | 2006-12-19 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases |
EP1797884B1 (en) * | 1999-12-06 | 2013-09-11 | Geistlich Pharma AG | Taurolidine or taurultam for use in the treatment of tumors of the prostate, colon, lung and for the treatment of recurrent glioblastoma multiforme |
CN100519525C (zh) | 1999-12-06 | 2009-07-29 | 葛兰素集团有限公司 | 芳香砜类及其医疗用途 |
US6641571B2 (en) | 2000-01-05 | 2003-11-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery |
CA2441016A1 (en) * | 2001-03-15 | 2002-09-26 | Paul Calabresi | Taurine compounds |
CA2462564C (en) | 2001-10-01 | 2012-07-10 | Rhode Island Hospital | Methods of inhibiting metastases |
AU2004201264B2 (en) | 2003-03-28 | 2009-12-24 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Adhesive Antineoplastic Compositions |
CA2482687C (en) | 2003-09-29 | 2012-11-20 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of mesothelioma |
EP2061429A2 (en) * | 2006-09-07 | 2009-05-27 | Ed. Geistlich Söhne Ag Für Chemische Industrie | Method of treating bone cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8328073D0 (en) * | 1983-10-20 | 1983-11-23 | Geistlich Soehne Ag | Chemical compounds |
-
1990
- 1990-07-09 GB GB909015108A patent/GB9015108D0/en active Pending
-
1991
- 1991-07-08 EP EP91911804A patent/EP0491018A1/en not_active Withdrawn
- 1991-07-08 WO PCT/EP1991/001269 patent/WO1992000743A1/en not_active Application Discontinuation
- 1991-07-08 JP JP51135891A patent/JP3465824B2/ja not_active Expired - Lifetime
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8304390B2 (en) | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
US9012444B2 (en) | 1999-06-04 | 2015-04-21 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
US7892530B2 (en) | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
US7910580B2 (en) | 1999-06-04 | 2011-03-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-Fluorouracil in treatment of tumor metastases and cancer |
US8030301B2 (en) | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
JP2012136540A (ja) * | 1999-12-06 | 2012-07-19 | Geistlich Pharma Ag | 腫瘍を治療する方法 |
JP2014198739A (ja) * | 1999-12-06 | 2014-10-23 | ガイストリッヒ ファーマ アーゲー | 腫瘍を治療する方法 |
JP2016188244A (ja) * | 1999-12-06 | 2016-11-04 | ガイストリッヒ ファーマ アーゲー | 腫瘍を治療する方法 |
JP2010043114A (ja) * | 2000-10-27 | 2010-02-25 | Ed Geistlich Soehne Ag Fuer Chemische Industrie | 腫瘍転移および癌の治療 |
JP2015163628A (ja) * | 2000-10-27 | 2015-09-10 | エド・ガイストリッヒ・ゼーネ・アクチェンゲゼルシャフト・フュール・ヒェミッシェ・インドゥストリーEd. Geistlich Soehne AG fuer chemische Industrie | 腫瘍転移および癌の治療 |
JP2017125050A (ja) * | 2000-10-27 | 2017-07-20 | エド・ガイストリッヒ・ゼーネ・アクチェンゲゼルシャフト・フュール・ヒェミッシェ・インドゥストリーEd. Geistlich Soehne AG fuer chemische Industrie | 腫瘍転移および癌の治療 |
JP2010043115A (ja) * | 2000-11-28 | 2010-02-25 | Ed Geistlich Soehne Ag Fuer Chemische Industrie | 腫瘍転移および癌の治療における5−フルオロウラシルの有効性の増強 |
JP2002363102A (ja) * | 2001-04-03 | 2002-12-18 | Ed Geistlich Soehne Ag Fuer Chemische Industrie | 新形成細胞の細胞消滅死を誘導する方法 |
Also Published As
Publication number | Publication date |
---|---|
JP3465824B2 (ja) | 2003-11-10 |
GB9015108D0 (en) | 1990-08-29 |
EP0491018A1 (en) | 1992-06-24 |
WO1992000743A1 (en) | 1992-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH05500973A (ja) | 化学的組成物 | |
Lee et al. | Melanoma: chemotherapy | |
DE69233169T2 (de) | Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor. | |
Goldie et al. | Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion pattern | |
JP2017125050A (ja) | 腫瘍転移および癌の治療 | |
Rodriguez et al. | Reduction of ifosfamide toxicity using dose fractionation | |
Ariel | Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors | |
JP2010043115A (ja) | 腫瘍転移および癌の治療における5−フルオロウラシルの有効性の増強 | |
KR960700063A (ko) | 사람 종양 세포내에서의 테모졸로마이드의 강화방법(Potentiation of temozolomide in human tumour cells) | |
EP0774255A1 (en) | Use of ursolic acid for the manufacture of a medicament for suppressing metastasis | |
Pazdur et al. | Phase II evaluation of fluorouracil and recombinant α‐2a‐interferon in previously untreated patients with pancreatic adenocarcinoma | |
JPS61129129A (ja) | 抗腫瘍剤 | |
Cortes et al. | Chemotherapy for head and neck cancer relapsing after radiotherapy | |
KR100742524B1 (ko) | 캄프토테신과 스틸벤 유도체를 포함하는 암 치료용 약제학적 병용제제 | |
TSUDA et al. | Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients | |
Hawkes | N-BENZYL-β-CHLOROPROPIONAMIDE (HIBICON®): A New Approach to Anticonvulsant Therapy | |
Jackson et al. | Treatment of vincristine-induced ileus with sincalide, a cholecystokinin analog | |
KR930702985A (ko) | 식도암의 치료 | |
Killen et al. | Phase II studies of methyl glyoxal bis‐guanylhydrazone (NSC 32946) in carcinoma of the colon and lung | |
Wright et al. | CLINICAL DRUG DOSAGES AND DURATION OF THERAPY OF THE CANCER CHEMOTHERAPEUTIC AGENTS¹ | |
JPS61129124A (ja) | 抗腫瘍剤 | |
JPH0211513A (ja) | 制癌剤 | |
Miki et al. | Antitumor effect of recombinant human tumor necrosis factor on human testicular tumors heterotransplanted in nude mice | |
JP2004331612A (ja) | 腰部脊柱管狭窄症による間歇跛行改善剤 | |
JPS595116A (ja) | 改良制癌剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070829 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080829 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090829 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100829 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100829 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110829 Year of fee payment: 8 |
|
EXPY | Cancellation because of completion of term |